Scalper1 News
Specialty drugmaker Mallinckrodt (MNK) offered fiscal 2016 guidance Tuesday following the sale of one of its imaging units, with revenue growth solid and EPS on the light side. The stock briefly rallied before being dragged down in another drug-stock sell-off. Mallinckrodt said that in the fiscal year ending Sept. 30 it expects to make $7.70 to $8.20 a share, bracketing analysts’ consensus of $8.00 but with the midpoint a bit below, according to Scalper1 News
Scalper1 News